NCT06461910 2026-03-03
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
Clinical Trials
18 trialsNCT06139419 2025-11-17
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06056804 2025-04-02
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
Phase 2 Active not recruiting
NCT06829355 2025-02-17
THYMI
Beijing Friendship Hospital
Phase 2 Recruiting
NCT06607926 2024-09-23
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Xuanwu Hospital, Beijing
Phase NA Not yet recruiting
NCT06584006 2024-09-19
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06598839 2024-09-19
Immuno-effect of Tα1 for Stage I NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Recruiting
NCT02535988 2023-09-21
Abscopal Effect for Metastatic Colorectal Cancer
Zhejiang Provincial People's Hospital
Phase 2 Withdrawn
NCT05790447 2023-03-30
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03659578 2022-01-03
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Completed
NCT02542137 2019-03-21
Abscopal Effect for Metastatic Small Cell Lung Cancer
Zhejiang Provincial People's Hospital
Phase 2 Withdrawn
NCT02545751 2017-11-28
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Hangzhou Cancer Hospital
Phase 2 Unknown
NCT02906150 2016-09-19
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
SciClone Pharmaceuticals
Phase 2 Unknown
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT00935558 2012-05-31
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Phase 2 Withdrawn
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed
NCT00082082 2008-01-15
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
SciClone Pharmaceuticals
Phase 2 Completed
NCT00580450 2007-12-24
Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
University Of Perugia
Phase 1/2 Unknown